Evidence map›Paper›PMID 42298884›Full record

ArticleClinical pharmacology and therapeutics2026

Use of Clinical Pharmacology in Slowing the Myopia Epidemic.

Gary D Novack

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gary D NovackPharmaLogic Development, Inc., San Rafael, California, USA.ORCID 0000-0002-9699-8543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myopia (nearsightedness) is in epidemic proportions in the world today. The eyecare community has long been desirous of pharmacological treatments to slow myopic progression. Most recently, two proprietary formulations of low-dose atropine were approved. In this article, the author summarizes the challenge to develop therapies for a chronic, preventative, and pediatric treatment, and how clinical pharmacologists' knowledge of pharmaceutics, pharmacokinetics, and therapeutics can optimize the development of therapies to slow myopic progression.

Indexed as

AtropineMyopiaPharmacology, ClinicalAnimalsDisease ProgressionHumansOphthalmic SolutionsAtropineOphthalmic Solutions

Identifiers

PMID42298884
PMCPMC13338982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.